GSK Blood Cancer Drug Returns to the U.S. Market, But New FDA Approval Is Still Limited

GSK drug Blenrep, which exited the market in 2022 after failing a confirmatory study, now has a new FDA approval as a third-line multiple myeloma treatment. The U.S. regulatory decision is more limited than the recent European approval for the blood cancer drug.

The post GSK Blood Cancer Drug Returns to the U.S. Market, But New FDA Approval Is Still Limited appeared first on MedCity News.